Jeffrey Feike
Net worth: 494 505 $ as of 2024-04-29
Profile
Jeffrey Feike currently works at Tevogen Bio Holdings, Inc., as Director from 2024.
Mr. Feike also formerly worked at Tevogen Bio, Inc., as Director & Chief Patient Officer.
Mr. Feike received his graduate degree from Tulane University (Louisiana).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.35% | 2024-02-13 | 581,771 ( 0.35% ) | 494 505 $ | 2024-04-29 |
Jeffrey Feike active positions
| Companies | Position | Start |
|---|
Former positions of Jeffrey Feike
| Companies | Position | End |
|---|---|---|
Tevogen Bio, Inc.
 Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Director/Board Member | - |
Training of Jeffrey Feike
| Tulane University (Louisiana) | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Tevogen Bio, Inc.
Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Jeffrey Feike
